Company Overview and News

KLCI off to muted start as key Maybank, CIMB drag

2018-10-16 theedgemarkets
KUALA LUMPUR (Oct 16): The FBM KLCI started off on a muted note this morning against teh backdrop of modest gains at regional markets, as key index-linked heavyweights dragged.
5183 MLYBY PECGF MLYNF BATS 4162 5246 7022 9059 CIMDF GBTKF 1155 1023

Petronas Dagangan 'buy', AWC 'add', Globetronics 'hold'

ANALYSTS expect Petronas Dagangan to generate stable operating margins in the coming years, with growing sales volume, post-implementation of effective inventory controls.
5681 7022 GBTKF

KLCI starts lower in line with frail regional markets

2018-10-12 theedgemarkets
KUALA LUMPUR (Oct 12): The FBM KLCI fell for the eighth day running this morning, amid frail regional sentiment.
HLFBF 3026 PBLOF 3867 5819 1082 1295 BSMAF 3034 7022 GBTKF 1818

Kenanga issues four new O&G warrants as oil breaches US$80

2018-10-01 theedgemarkets
KUALA LUMPUR (Oct 1): Kenanga Investment Bank Bhd (KIBB) has issued four new structured warrants covering the O&G sector, just as Brent crude oil prices surpassed US$80 a barrel this week.
0166 BRDBF 7022 5012 GBTKF 5210

KLCI tracks regional gains, select blue chips lift

2018-09-14 theedgemarkets
KUALA LUMPUR (Sept 14): The FBM KLCI edged up in early trade this morning, lifted by select blue chips, tracking gains at most regional markets.
4634 7084 1023 5260 7022 GEBHF GBTKF CIMDF

Chinese firm leads takeover for Unisem at RM3.30 per share

2018-09-13 theedgemarkets
KUALA LUMPUR: Unisem (M) Bhd's controlling shareholder John Chia and China’s Tianshui Huatian Technology Co Ltd (TSHT) are making a pre-conditional voluntary conditional takeover offer for the semiconductor firm at RM3.30 per share — a 11.11% premium over the last traded price before the announcement.
3867 7022 GBTKF

‘Electronic industry is not slowing down’

“The growth was supported by demand from the new generation cars and the high demand of power electronics devices in the hybrid and electric vehicle (EV) car control system. “We noticed the trend three years ago and started to develop test equipment for testing automotive sensors,” Chuah said. (Pentamaster Corporation Berhad executive chairman Chuah Choon Bin (second from right) checking out a test equipment.
7160 7022 GBTKF

Globetronics eyes 2-digit growth, plans RM60bil expansion

Group chief executive officer Datuk Heng Huck Lee(inset) said the group was confident of achieving its target with a strong double-digit percentage growth for its gross profit.
7022 GBTKF

O&G profits under spotlight for signs of real recovery

2018-08-13 theedgemarkets
KUALA LUMPUR: An unexpected bright spot this year, the oil and gas (O&G) sector is expected to continue on a recovery path with upstream companies gradually stepping up production and boosting other firms involved in the industry.
5681 7022 7277 GBTKF

Malaysian chip and plastic makers gain from trade war

Globetronics Technology Berhad's chairman and chief executive officer Michael Ng (left) and chief operating officer Heng Huck Lee (right) showing some products of the group. - Filepic
7248 7022 7034 GBTKF

Bursa tech stocks advance as global semiconductor sales continue to grow

2018-08-06 theedgemarkets
KUALA LUMPUR (Aug 6): The Technology Index on Bursa Malaysia was the top gainer on the Malaysian stock exchange as it jumped by 1.04% to 38.85 points following stronger global semiconductor sales during the first half of the year.
0166 8338 AAPL BSMAF 7022 GBTKF 1818

Stronger H2 seen for Globetronics

Its sensor production volume in the first half was three times higher than the same period last year, driven by higher gesture sensor volumes and contribution from the light sensors.
7022 GBTKF

Globetronics shares jump; trading volume surges

2018-08-01 theedgemarkets
KUALA LUMPUR (August 1): Globetronics Technology Bhd shares rose 5.6 percent, while Malaysia's benchmark index declined.
7022 GBTKF

Volume and forex push Globetronics profit higher

PETALING JAYA: Globetronics Technology Bhd ’s net profit for its second quarter ended June 30 rose 32% to RM9.34mil from RM7.06mil in the previous corresponding period.
BSMAF 7022 GBTKF 1818

KLCI seen starting off August on a positive note, support at 1,770-level

2018-07-31 theedgemarkets
KUALA LUMPUR (Aug 1): The FBM KLCI is seen starting off August on a positive note today, in line with the overnight gains at most global markets, with support at the 1,770-point level.
5436 5216 0035 7158 5151 7022 GBTKF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...